Avidicure (avidicure.com): no confident changes recorded yet; website history since April 2025. Homepage last checked 5 November 2026.
First recorded website
Observed 3 October 2025
Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
Avidicure is developing dual agonistic avidity-engineered multifunctional antibodies, AVC-Boosters, as monotherapy for treatment of cancer